- Home
- AHG vs PRTC Comparison
AHG vs PRTC Comparison
Compare AHG & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AHG
- PRTC
- Stock Information
- Founded
- AHG 2013
- PRTC 2015
- Country
- AHG China
- PRTC United States
- Employees
- AHG N/A
- PRTC N/A
- Industry
- AHG Business Services
- PRTC Biotechnology: Pharmaceutical Preparations
- Sector
- AHG Consumer Discretionary
- PRTC Health Care
- Exchange
- AHG Nasdaq
- PRTC Nasdaq
- Market Cap
- AHG 502.5M
- PRTC 414.6M
- IPO Year
- AHG N/A
- PRTC N/A
- Fundamental
- Price
- AHG $1.42
- PRTC $17.25
- Analyst Decision
- AHG
- PRTC Buy
- Analyst Count
- AHG 0
- PRTC 1
- Target Price
- AHG N/A
- PRTC $45.00
- AVG Volume (30 Days)
- AHG 22.0K
- PRTC 4.0K
- Earning Date
- AHG 05-16-2025
- PRTC 04-30-2025
- Dividend Yield
- AHG N/A
- PRTC N/A
- EPS Growth
- AHG N/A
- PRTC N/A
- EPS
- AHG N/A
- PRTC 0.21
- Revenue
- AHG $8,454,946.00
- PRTC $4,828,000.00
- Revenue This Year
- AHG N/A
- PRTC $35.98
- Revenue Next Year
- AHG N/A
- PRTC $115.38
- P/E Ratio
- AHG N/A
- PRTC $7.39
- Revenue Growth
- AHG 281.19
- PRTC 44.98
- 52 Week Low
- AHG $0.60
- PRTC $13.30
- 52 Week High
- AHG $2.35
- PRTC $32.98
- Technical
- Relative Strength Index (RSI)
- AHG 61.79
- PRTC 49.49
- Support Level
- AHG $1.34
- PRTC $17.41
- Resistance Level
- AHG $1.45
- PRTC $18.05
- Average True Range (ATR)
- AHG 0.14
- PRTC 0.39
- MACD
- AHG 0.02
- PRTC 0.06
- Stochastic Oscillator
- AHG 77.66
- PRTC 54.70
About AHG Akso Health Group ADS
Akso Health Group formerly Xiaobai Maimai Inc is a social e-commerce platform based in China. The company collaborates with domestic e-commerce platforms and offers users a wide selection of high-quality and affordable products on its social e-commerce platform. It generates majority of the revenues from sale of medical devices business.
About PRTC PureTech Health plc
PureTech Health PLC is a biopharma company developing medicines to modulate the adaptive human system. It is a cross-disciplinary healthcare company developing products that could improve the lives of patients. The company is focused on developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic, and immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological & neuropsychological disorders, among others. It operates in the following segments: Wholly-Owned Programs, Controlled Founded Entities, and Parent Companies & Others. The company has a robust pipeline of advanced programs that are post-human proof of concept and focused on some of society's healthcare needs.